IBS: ANCHE LA PERDITA DELLA INTEGRITA’ DELLA BARRIERA EPITELIALE CONTRIBUISCE. UN GRANDE STUDIO DA BOLOGNA ! DA”GASTROENTEROLOGY”

DISORDINI FUNZIONALI, GASTROENTEROLOGIA, IBS, INTERNATIONAL SNAPSHOTS, NUTRIZIONE, Senza categoria

Molecular Mechanisms Underlying Loss of Vascular and Epithelial Integrity in Irritable Bowel Syndrome Maria Raffaella Barbaro et al. Abstract Background & Aims The pathophysiology of irritable bowel syndrome (IBS) is multifactorial and includes epithelial barrier dysfunction, a key element at the interface between the gut lumen and the deeper intestinal layers. Beneath the epithelial barrier…

OCCHIO ALLA DIETA, O IBDOLOGI! LE NUOVE LINEE GUIDA AMERICANE PER DIETA E TERAPIA NUTRIZIONALE NELLE IBD. DA “GASTROENTEROLOGY” (FREE)

GASTROENTEROLOGIA, IBD, LINEE GUIDA EBM, MEDICINA INTERNA, NUTRIZIONE, Senza categoria

AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review Jana G. Hashash et al. Abstract Description Diet plays a critical role in human health, but especially for patients with inflammatory bowel disease (IBD). Guidance about diet for patients with IBD are often controversial and a source of uncertainty…

INFLIXIMAB SOTTOCUTE COME TERAPIA DI MANTENIMENTO FUNZIONA DOPO LA INDUZIONE ENDOVENA. LA ANALISI POST-HOC DI DUE TRIAL. DA “Gastroenterology” (FREE)

GASTROENTEROLOGIA, IBD, Senza categoria

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY) Stephen B Hanauer et al. Abstract Background & aims: CT-P13 subcutaneous (SC), an SC formulation of the intravenous (IV) infliximab biosimilar CT-P13 IV, creates a unique exposure profile. The LIBERTY studies aimed to demonstrate superiority of CT-P13 SC vs…

MODULATORI CENTRALI PER I DISORDINI FUNZIONALI ESOFAGEI. UNA BUONA META-ANALISI ! DOLORE FUNZIONALE TORACICO, GLOBO, DISFAGIA FUNZIONALE….DA “DIGESTIVE & LIVER DISEASE” (FREE)

ENDOSCOPIA, GASTROENTEROLOGIA, MEDICINA INTERNA, Senza categoria

Central neuromodulators for patients with functional esophageal disorders: A systematic review and meta-analysis Jen-Hao Yeh et al. Abstract Backgroud: The use of neuromodulators is prevalent in various functional gastrointestinal disease. However, data concerning the outcomes of these treatments in functional esophageal disorders (FED) remains limited and inadequate. Aims: The aim of the present study is to examine…

OCCHIO GASTROENTEROLOGI! E’ COMPARSO UN OTTIMO ARTICOLO DI FACCIORUSSO & COLL PER CALCOLARE IL SAMPLE SIZE PER IL VOSTRO PROX STUDIO! DA “Expert Review of Gastroenterology & Hepatology”

GASTROENTEROLOGIA, MEDICINA INTERNA, PANCREAS E VIE BILIARI, REAL WORLD EVIDENCE

Principle of sample size calculation in gastroenterology research: a practical guide for clinicians Antonio Facciorusso et al. ABSTRACT Introduction A proper sample size calculation enables to conduct adequately powered randomized controlled trials (RCTs) and to provide a valid assessment of a specific clinical question. Areas covered In the current manuscript, we tried to provide the…

I RISCHI DEL PLACEBO NEI TRIAL CON BIOLOGICI E CON “SMALL MOLECULES” PER LE IBD. UN’IMPORTANTE META-ANALISI. PEGGIORAMENTO DELLA ATTIVITA’ DELLA IBD + 8.5%. NON SARA’ TEMPO DI SOSPENDERE I TRIAL CONTRO PLACEBO NELLE IBD? DA “THE LANCET” (FREE)

GASTROENTEROLOGIA, IBD, METODOLOGIA, Senza categoria

Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis Shahida Din et al. Summary Background Randomised placebo-controlled trials are the gold standard to assess novel drugs in ulcerative colitis and Crohn’s disease. However, there might be risks associated with receiving placebo. We…